{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:34:52Z","timestamp":1792812892314,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01305-w","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T20:48:07Z","timestamp":1756241287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Global Epidemiology of PD-L1 Expression in Epstein-Barr Virus-Associated Gastric Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8707-4823","authenticated-orcid":false,"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3006-5489","authenticated-orcid":false,"given":"Luis Eduardo Rodrigues","family":"Sobreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3529-5489","authenticated-orcid":false,"given":"Shi Juin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3453-8736","authenticated-orcid":false,"given":"Mariana Rachas","family":"Reis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"issue":"7517","key":"1305_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B, et al. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139.","journal-title":"Nature"},{"issue":"3","key":"1305_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1305_CR3","doi-asserted-by":"publisher","first-page":"17036","DOI":"10.1038\/nrdp.2017.36","volume":"3","author":"JA Ajani","year":"2017","unstructured":"Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017;3:17036.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1305_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.26444\/jpccr\/81214","volume":"11","author":"E Kliszczewska","year":"2017","unstructured":"Kliszczewska E, Jarzy\u0144ski A, Boguszewska A, Pasternak J, Polz-Dacewicz M. Epstein-Barr Virus \u2013 pathogenesis, latency and cancers. J Pre Clin Clin Res. 2017;11(2):142\u20136.","journal-title":"J Pre Clin Clin Res"},{"key":"1305_CR5","doi-asserted-by":"publisher","first-page":"1202117","DOI":"10.3389\/fonc.2023.1202117","volume":"13","author":"YH Low","year":"2023","unstructured":"Low YH, Loh CJL, Peh DYY, Chu AJM, Han S, Toh HC. Pathogenesis and therapeutic implications of EBV-associated epithelial cancers. Front Oncol. 2023;13:1202117.","journal-title":"Front Oncol"},{"key":"1305_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev. 2018;66:15\u201322.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1305_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s10120-020-01095-z","volume":"23","author":"E Ignatova","year":"2020","unstructured":"Ignatova E, Seriak D, Fedyanin M, Tryakin A, Pokataev I, Menshikova S, et al. Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020;23(6):951\u201360.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1305_CR8","doi-asserted-by":"publisher","first-page":"320","DOI":"10.4103\/bbrj.bbrj_227_24","volume":"8","author":"M Patel","year":"2024","unstructured":"Patel M, Singh P, Gandupalli L, Gupta R. Identification and evaluation of survival-associated common chemoresistant genes in cancer. Biomedical and Biotechnology Research Journal (BBRJ). 2024;8(3):320.","journal-title":"Biomedical and Biotechnology Research Journal (BBRJ)"},{"key":"1305_CR9","doi-asserted-by":"publisher","first-page":"1358511","DOI":"10.3389\/fimmu.2024.1358511","volume":"15","author":"MY Salnikov","year":"2024","unstructured":"Salnikov MY, MacNeil KM, Mymryk JS. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape. Front Immunol. 2024;15:1358511.","journal-title":"Front Immunol"},{"issue":"1","key":"1305_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13027-023-00489-9","volume":"18","author":"G Li","year":"2023","unstructured":"Li G, Zhou Z, Wang Z, Wang Z. Assessing Epstein-Barr virus in gastric cancer: clinicopathological features and prognostic implications. Infectious Agents and Cancer. 2023;18(1):11.","journal-title":"Infectious Agents and Cancer"},{"issue":"12","key":"1305_CR11","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.3390\/cancers15123248","volume":"15","author":"R Pihlak","year":"2023","unstructured":"Pihlak R, Fong C, Starling N. Targeted therapies and developing precision medicine in gastric cancer. Cancers (Basel). 2023;15(12):3248.","journal-title":"Cancers (Basel)"},{"issue":"44","key":"1305_CR12","doi-asserted-by":"publisher","first-page":"6249","DOI":"10.3748\/wjg.v28.i44.6249","volume":"28","author":"H Iizasa","year":"2022","unstructured":"Iizasa H, Kartika AV, Fekadu S, Okada S, Onomura D, Wadi AFAA, et al. Development of Epstein-Barr virus-associated gastric cancer: Infection, inflammation, and oncogenesis. World J Gastroenterol. 2022;28(44):6249\u201357.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1305_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12885-023-10605-y","volume":"23","author":"G Huo","year":"2023","unstructured":"Huo G, Liu W, Chen P. Efficacy of PD-1\/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. BMC Cancer. 2023;23(1):143.","journal-title":"BMC Cancer"},{"key":"1305_CR14","doi-asserted-by":"crossref","unstructured":"Chen T-T. Milestone Survival: A potential intermediate endpoint for immune checkpoint inhibitors. J Natl Cancer Inst. 2015 Sep;107(9):djv156.","DOI":"10.1093\/jnci\/djv156"},{"issue":"1","key":"1305_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12029-024-01141-4","volume":"56","author":"FCA de Moraes","year":"2025","unstructured":"de Moraes FCA, Sano VKT, Silva BL, Silva ALS, Castro SCR, Kreuz M, et al. PD-1\/PD-L1 inhibitors increase pathological complete response in locally advanced gastric cancer: A meta-analysis and trial sequential analysis. J Gastrointest Cancer. 2025;56(1):49.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"1305_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jtho.2019.12.107","volume":"15","author":"S Lantuejoul","year":"2020","unstructured":"Lantuejoul S, Sound-Tsao M, Cooper WA, Girard N, Hirsch FR, Roden AC, et al. PD-L1 testing for lung cancer in 2019: Perspective from the IASLC pathology committee. J Thorac Oncol. 2020;15(4):499\u2013519.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1305_CR17","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.3390\/ijms22105123","volume":"22","author":"E Munari","year":"2021","unstructured":"Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, et al. PD-1\/PD-L1 in cancer: Pathophysiological, diagnostic and therapeutic aspects. Int J Mol Sci. 2021;22(10):5123.","journal-title":"Int J Mol Sci"},{"issue":"2\u20133","key":"1305_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1053\/j.seminoncol.2020.04.001","volume":"47","author":"A Piku\u0142a","year":"2020","unstructured":"Piku\u0142a A, Kwietniewska M, Rawicz-Pruszy\u0144ski K, Cise\u0142 B, Sk\u00f3rzewska M, G\u0119ca K, et al. The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer. Semin Oncol. 2020;47(2\u20133):127\u201337.","journal-title":"Semin Oncol"},{"key":"1305_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"1305_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.","journal-title":"Syst Rev"},{"key":"1305_CR21","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"issue":"4","key":"1305_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/XEB.0000000000000141","volume":"16","author":"L Furuya-Kanamori","year":"2018","unstructured":"Furuya-Kanamori L, Barendregt JJ, Doi SAR. A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid Based Healthc. 2018;16(4):195\u2013203.","journal-title":"Int J Evid Based Healthc"},{"key":"1305_CR23","doi-asserted-by":"publisher","first-page":"103550","DOI":"10.1016\/j.ajp.2023.103550","volume":"84","author":"MA Shamim","year":"2023","unstructured":"Shamim MA, Dwivedi P, Padhi BK. Beyond the funnel plot: The advantages of Doi plots and prediction intervals in meta-analyses. Asian J Psychiatr. 2023;84:103550.","journal-title":"Asian J Psychiatr"},{"key":"1305_CR24","doi-asserted-by":"crossref","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139.","DOI":"10.3322\/caac.21388"},{"key":"1305_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jss.2024.01.043","volume":"296","author":"EJ Yee","year":"2024","unstructured":"Yee EJ, Gilbert D, Kaplan J, van Dyk L, Kim SS, Berg L, et al. Immune landscape of epstein-barr virus-associated gastric cancer: Analysis from a western academic institution. J Surg Res. 2024;296:742\u201350.","journal-title":"J Surg Res"},{"issue":"6","key":"1305_CR26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/his.14869","volume":"82","author":"K van der Sluis","year":"2023","unstructured":"van der Sluis K, van Sandick JW, van Dieren JM, Vollebergh MA, Grootscholten C, van den Berg JG, et al. The clinical impact of testing for biomarkers in gastric cancer patients: a real-world cohort. Histopathology. 2023;82(6):826\u201336.","journal-title":"Histopathology"},{"issue":"4","key":"1305_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1615\/JEnvironPatholToxicolOncol.2023047662","volume":"42","author":"G Issin","year":"2023","unstructured":"Issin G, Sayar \u0130, Demir F, Bakkalo\u011flu \u0130G, Gamsizkan M, Yildiz Z, et al. Clinicopathologic features and prognostic significance of immunohistochemistry and in situ hybridization based molecular classification in gastric carcinoma. J Environ Pathol Toxicol Oncol. 2023;42(4):1\u201314.","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"1305_CR28","unstructured":"Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan - PubMed [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35220884\/"},{"key":"1305_CR29","unstructured":"Prognostic Perspectives of STING and PD-L1 Expression and Correlation with the Prognosis of Epstein-Barr Virus-Associated Gastric Cancers - PubMed [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/35611665\/"},{"issue":"2","key":"1305_CR30","first-page":"83","volume":"123","author":"L Stanek","year":"2022","unstructured":"Stanek L, Gurlich R, Musil Z, Havluj L, Whitley A. Monitoring EBV infection, MSI, PDL-1 expression, Her-2\/neu amplification as a biomarker for PD-1 inhibition in gastric cancer. Bratisl Lek Listy. 2022;123(2):83\u20136.","journal-title":"Bratisl Lek Listy"},{"key":"1305_CR31","doi-asserted-by":"publisher","first-page":"2684065","DOI":"10.1155\/2022\/2684065","volume":"2022","author":"J Shi","year":"2022","unstructured":"Shi J, Yang X, Wang X, Luo Y, Zhou W, Luo H, et al. Prevalence of Epstein-Barr virus infection and mismatch repair protein deficiency and the correlation of immune markers in Tibetan patients with gastric cancer. Biomed Res Int. 2022;2022:2684065.","journal-title":"Biomed Res Int"},{"key":"1305_CR32","doi-asserted-by":"publisher","first-page":"154108","DOI":"10.1016\/j.prp.2022.154108","volume":"238","author":"H-N Kim","year":"2022","unstructured":"Kim H-N, Ahn S, Kim K-M. Gastric cancer with Epstein-Barr virus heterogeneity: Evaluation of the frequency, clinicopathologic features, and genomic profiles. Pathol Res Pract. 2022;238:154108.","journal-title":"Pathol Res Pract"},{"issue":"7","key":"1305_CR33","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3390\/cancers14071736","volume":"14","author":"B Dislich","year":"2022","unstructured":"Dislich B, Mertz KD, Gloor B, Langer R. Interspatial distribution of tumor and immune cells in correlation with PD-L1 in molecular subtypes of gastric cancers. Cancers (Basel). 2022;14(7):1736.","journal-title":"Cancers (Basel)"},{"key":"1305_CR34","doi-asserted-by":"publisher","first-page":"783695","DOI":"10.3389\/fimmu.2022.783695","volume":"13","author":"X Chen","year":"2022","unstructured":"Chen X, Zhang H, Wang M, Liu H, Hu Y, Lin T, et al. Relationship between programmed death ligand 1 expression and other clinicopathological features in a large cohort of gastric cancer patients. Front Immunol. 2022;13:783695.","journal-title":"Front Immunol"},{"key":"1305_CR35","doi-asserted-by":"crossref","unstructured":"de F\u00e1tima Aquino Moreira-Nunes C, de Souza Almeida Titan Martins CN, Feio D, Lima IK, Lamar\u00e3o LM, de Souza CRT, et al. PD-L1 expression associated with Epstein-Barr virus status and patients\u2019 survival in a large cohort of gastric cancer patients in Northern Brazil. Cancers (Basel). 2021;13(13):3107.","DOI":"10.3390\/cancers13133107"},{"key":"1305_CR36","doi-asserted-by":"publisher","first-page":"9980410","DOI":"10.1155\/2021\/9980410","volume":"2021","author":"JP Nshizirungu","year":"2021","unstructured":"Nshizirungu JP, Bennis S, Mellouki I, Sekal M, Benajah D-A, Lahmidani N, et al. Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) gastric cancer molecular classifications and their association with clinicopathological characteristics and overall survival in Moroccan patients. Dis Markers. 2021;2021:9980410.","journal-title":"Dis Markers"},{"key":"1305_CR37","doi-asserted-by":"publisher","first-page":"e11481","DOI":"10.7717\/peerj.11481","volume":"9","author":"N Yang","year":"2021","unstructured":"Yang N, Wu Y, Jin M, Jia Z, Wang Y, Cao D, et al. Microsatellite instability and Epstein-Barr virus combined with PD-L1 could serve as a potential strategy for predicting the prognosis and efficacy of postoperative chemotherapy in gastric cancer. PeerJ. 2021;9:e11481.","journal-title":"PeerJ"},{"key":"1305_CR38","unstructured":"Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas - PubMed [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/32498695\/"},{"key":"1305_CR39","unstructured":"Her2-Positive and Microsatellite Instability Status in Gastric Cancer\u2014Clinicopathological Implications - PMC [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8228707\/"},{"issue":"6","key":"1305_CR40","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3390\/cancers12061517","volume":"12","author":"W-L Fang","year":"2020","unstructured":"Fang W-L, Chen M-H, Huang K-H, Lin C-H, Chao Y, Lo S-S, et al. The clinicopathological features and genetic alterations in Epstein-Barr virus-associated gastric cancer patients after curative surgery. Cancers (Basel). 2020;12(6):1517.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1305_CR41","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.21873\/invivo.12152","volume":"34","author":"DH Kim","year":"2020","unstructured":"Kim DH, Bae GE, Suh KS, Ryuman D, Song KS, Kim JS, et al. Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma. In Vivo. 2020;34(6):3171\u201380.","journal-title":"In Vivo"},{"issue":"4","key":"1305_CR42","doi-asserted-by":"publisher","first-page":"152881","DOI":"10.1016\/j.prp.2020.152881","volume":"216","author":"X Liu","year":"2020","unstructured":"Liu X, Choi MG, Kim K, Kim K-M, Kim ST, Park SH, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216(4):152881.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"1305_CR43","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/cancers12010198","volume":"12","author":"HA Martinson","year":"2020","unstructured":"Martinson HA, Mallari D, Richter C, Wu T-T, Tiesinga J, Alberts SR, et al. Molecular classification of gastric cancer among Alaska native people. Cancers (Basel). 2020;12(1):198.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"1305_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000316","volume":"43","author":"T Xie","year":"2020","unstructured":"Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C, et al. Positive status of Epstein-Barr Virus as a biomarker for gastric cancer immunotherapy: A prospective observational study. J Immunother. 2020;43(4):139\u201344.","journal-title":"J Immunother"},{"issue":"1","key":"1305_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s10120-018-0836-8","volume":"22","author":"I Gullo","year":"2019","unstructured":"Gullo I, Oliveira P, Athelogou M, Gon\u00e7alves G, Pinto ML, Carvalho J, et al. New insights into the inflamed tumor immune microenvironment of gastric cancer with lymphoid stroma: from morphology and digital analysis to gene expression. Gastric Cancer. 2019;22(1):77\u201390.","journal-title":"Gastric Cancer"},{"key":"1305_CR46","unstructured":"Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer - PubMed [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29859006\/"},{"issue":"4","key":"1305_CR47","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/ijc.32140","volume":"145","author":"Y-B Kim","year":"2019","unstructured":"Kim Y-B, Ahn JM, Bae WJ, Sung CO, Lee D. Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer. Int J Cancer. 2019;145(4):916\u201326.","journal-title":"Int J Cancer"},{"issue":"6","key":"1305_CR48","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s10120-019-00974-4","volume":"22","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kim WG, Kwon CH, Park DY. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer. 2019;22(6):1164\u201375.","journal-title":"Gastric Cancer"},{"issue":"1","key":"1305_CR49","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7(1):24.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1305_CR50","doi-asserted-by":"publisher","first-page":"e0211358","DOI":"10.1371\/journal.pone.0211358","volume":"14","author":"A Nakayama","year":"2019","unstructured":"Nakayama A, Abe H, Kunita A, Saito R, Kanda T, Yamashita H, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in Epstein-Barr Virus-associated gastric carcinoma. PLoS ONE. 2019;14(1):e0211358.","journal-title":"PLoS ONE"},{"key":"1305_CR51","unstructured":"Predictive value of WHO classification for PD-L1 and Her2\/Neu expression and distinct associations with protein expression based classification in gastric carcinoma - PubMed [Internet]. [cited 2025 Feb 18]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31676362\/"},{"key":"1305_CR52","doi-asserted-by":"publisher","first-page":"6397","DOI":"10.2147\/CMAR.S206189","volume":"11","author":"Y Sun","year":"2019","unstructured":"Sun Y, Yu W, Guan W, Cai L, Qiao M, Zheng L, et al. Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer. Cancer Manag Res. 2019;11:6397\u2013410.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"1305_CR53","first-page":"1775","volume":"18","author":"AM Valentini","year":"2019","unstructured":"Valentini AM, Di Pinto F, Coletta S, Guerra V, Armentano R, Caruso ML. Tumor microenvironment immune types in gastric cancer are associated with mismatch repair however, not HER2 status. Oncol Lett. 2019;18(2):1775\u201385.","journal-title":"Oncol Lett"},{"issue":"12","key":"1305_CR54","doi-asserted-by":"publisher","first-page":"e0224812","DOI":"10.1371\/journal.pone.0224812","volume":"14","author":"J-Y Yoon","year":"2019","unstructured":"Yoon J-Y, Sy K, Brezden-Masley C, Streutker CJ. Histo- and immunohistochemistry-based estimation of the TCGA and ACRG molecular subtypes for gastric carcinoma and their prognostic significance: A single-institution study. PLoS ONE. 2019;14(12):e0224812.","journal-title":"PLoS ONE"},{"issue":"1","key":"1305_CR55","doi-asserted-by":"publisher","first-page":"13887","DOI":"10.1038\/s41598-018-32299-0","volume":"8","author":"YH Chang","year":"2018","unstructured":"Chang YH, Heo YJ, Cho J, Song SY, Lee J, Kim K-M. Computational measurement of tumor immune microenvironment in gastric adenocarcinomas. Sci Rep. 2018;8(1):13887.","journal-title":"Sci Rep"},{"issue":"6","key":"1305_CR56","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s10120-018-0820-3","volume":"21","author":"CJ Cho","year":"2018","unstructured":"Cho CJ, Kang HJ, Ryu Y-M, Park YS, Jeong HJ, Park Y-M, et al. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype. Gastric Cancer. 2018;21(6):925\u201335.","journal-title":"Gastric Cancer"},{"issue":"4","key":"1305_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/cancers10040102","volume":"10","author":"S De Rosa","year":"2018","unstructured":"De Rosa S, Sahnane N, Tibiletti MG, Magnoli F, Vanoli A, Sessa F, et al. EBV+ and MSI gastric cancers harbor high PD-L1\/PD-1 expression and high CD8+ intratumoral lymphocytes. Cancers (Basel). 2018;10(4):102.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1305_CR58","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3390\/ijms19072079","volume":"19","author":"I Gullo","year":"2018","unstructured":"Gullo I, Carvalho J, Martins D, Lemos D, Monteiro AR, Ferreira M, et al. The transcriptomic landscape of gastric cancer: Insights into Epstein-Barr virus infected and microsatellite unstable tumors. Int J Mol Sci. 2018;19(7):2079.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1305_CR59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/PAS.0000000000001018","volume":"42","author":"E Hissong","year":"2018","unstructured":"Hissong E, Ramrattan G, Zhang P, Zhou XK, Young G, Klimstra DS, et al. Gastric carcinomas with lymphoid stroma: An evaluation of the histopathologic and molecular features. Am J Surg Pathol. 2018;42(4):453\u201362.","journal-title":"Am J Surg Pathol"},{"key":"1305_CR60","unstructured":"Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes [Internet]. [cited 2025 Feb 18]. Available from: http:\/\/www.annclinlabsci.org\/content\/48\/6\/695.long"},{"issue":"5","key":"1305_CR61","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/jso.25022","volume":"117","author":"MA Pereira","year":"2018","unstructured":"Pereira MA, Ramos MFKP, Faraj SF, Dias AR, Yagi OK, Zilberstein B, et al. Clinicopathological and prognostic features of Epstein-Barr virus infection, microsatellite instability, and PD-L1 expression in gastric cancer. J Surg Oncol. 2018;117(5):829\u201339.","journal-title":"J Surg Oncol"},{"issue":"6","key":"1305_CR62","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1007\/s10120-018-0851-9","volume":"21","author":"R Sundar","year":"2018","unstructured":"Sundar R, Qamra A, Tan ALK, Zhang S, Ng CCY, Teh BT, et al. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes. Gastric Cancer. 2018;21(6):1064\u201370.","journal-title":"Gastric Cancer"},{"issue":"3","key":"1305_CR63","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407\u201315.","journal-title":"Gastric Cancer"},{"issue":"16","key":"1305_CR64","doi-asserted-by":"publisher","first-page":"26356","DOI":"10.18632\/oncotarget.15465","volume":"8","author":"J Koh","year":"2017","unstructured":"Koh J, Ock C-Y, Kim JW, Nam SK, Kwak Y, Yun S, et al. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget. 2017;8(16):26356\u201367.","journal-title":"Oncotarget"},{"issue":"47","key":"1305_CR65","doi-asserted-by":"publisher","first-page":"82399","DOI":"10.18632\/oncotarget.19390","volume":"8","author":"MJ Kwon","year":"2017","unstructured":"Kwon MJ, Kim K-C, Nam ES, Cho SJ, Park H-R, Min SK, et al. Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget. 2017;8(47):82399\u2013414.","journal-title":"Oncotarget"},{"issue":"40","key":"1305_CR66","doi-asserted-by":"publisher","first-page":"67094","DOI":"10.18632\/oncotarget.17945","volume":"8","author":"J Ma","year":"2017","unstructured":"Ma J, Li J, Hao Y, Nie Y, Li Z, Qian M, et al. Differentiated tumor immune microenvironment of Epstein-Barr virus-associated and negative gastric cancer: implication in prognosis and immunotherapy. Oncotarget. 2017;8(40):67094\u2013103.","journal-title":"Oncotarget"},{"issue":"3","key":"1305_CR67","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/modpathol.2016.202","volume":"30","author":"R Saito","year":"2017","unstructured":"Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol. 2017;30(3):427\u201339.","journal-title":"Mod Pathol"},{"issue":"12","key":"1305_CR68","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/bjc.2017.369","volume":"117","author":"AN Seo","year":"2017","unstructured":"Seo AN, Kang BW, Kwon OK, Park KB, Lee SS, Chung HY, et al. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Br J Cancer. 2017;117(12):1753\u201360.","journal-title":"Br J Cancer"},{"issue":"5","key":"1305_CR69","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1136\/gutjnl-2015-310839","volume":"66","author":"ED Thompson","year":"2017","unstructured":"Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 2017;66(5):794\u2013801.","journal-title":"Gut"},{"issue":"38","key":"1305_CR70","doi-asserted-by":"publisher","first-page":"64066","DOI":"10.18632\/oncotarget.19318","volume":"8","author":"Y Wu","year":"2017","unstructured":"Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, et al. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8(38):64066\u201382.","journal-title":"Oncotarget"},{"issue":"17","key":"1305_CR71","doi-asserted-by":"publisher","first-page":"24269","DOI":"10.18632\/oncotarget.8169","volume":"7","author":"C B\u00f6ger","year":"2016","unstructured":"B\u00f6ger C, Behrens H-M, Mathiak M, Kr\u00fcger S, Kalthoff H, R\u00f6cken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016;7(17):24269\u201383.","journal-title":"Oncotarget"},{"issue":"10","key":"1305_CR72","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/j.molonc.2016.09.004","volume":"10","author":"C Dai","year":"2016","unstructured":"Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, et al. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. 2016;10(10):1551\u20138.","journal-title":"Mol Oncol"},{"issue":"22","key":"1305_CR73","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","volume":"7","author":"S Derks","year":"2016","unstructured":"Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7(22):32925\u201332.","journal-title":"Oncotarget"},{"key":"1305_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2016.02.007","volume":"53","author":"M Dong","year":"2016","unstructured":"Dong M, Wang H-Y, Zhao X-X, Chen J-N, Zhang Y-W, Huang Y, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. Hum Pathol. 2016;53:25\u201334.","journal-title":"Hum Pathol"},{"issue":"11","key":"1305_CR75","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1245\/s10434-016-5284-2","volume":"23","author":"HJ Kang","year":"2016","unstructured":"Kang HJ, Lee I-S, Park Y-S, Ho WJ, Sohn D, Ahn J-Y, et al. Biomarkers of EBV-positive gastric cancers: Loss of PTEN expression is associated with poor prognosis and nodal metastasis. Ann Surg Oncol. 2016;23(11):3684\u201392.","journal-title":"Ann Surg Oncol"},{"key":"1305_CR76","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.humpath.2016.05.012","volume":"55","author":"Z Li","year":"2016","unstructured":"Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 2016Sep;55:182\u20139.","journal-title":"Hum Pathol"},{"issue":"11","key":"1305_CR77","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1097\/PAS.0000000000000698","volume":"40","author":"C Ma","year":"2016","unstructured":"Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am J Surg Pathol. 2016;40(11):1496\u2013506.","journal-title":"Am J Surg Pathol"},{"key":"1305_CR78","doi-asserted-by":"crossref","unstructured":"de Moraes FCA, Pasqualotto E, Chavez MP, Ferreira ROM, De Castria TB, Burbano RMR. Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. BMC Cancer. 2024;24(1):240.","DOI":"10.1186\/s12885-024-11980-w"},{"issue":"5","key":"1305_CR79","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jmedgenet-2016-104171","volume":"54","author":"X-Y Zhang","year":"2017","unstructured":"Zhang X-Y, Zhang P-Y. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2017;54(5):305\u201312.","journal-title":"J Med Genet"},{"issue":"11","key":"1305_CR80","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.3390\/ijms21114012","volume":"21","author":"J Machlowska","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.","journal-title":"Int J Mol Sci"},{"key":"1305_CR81","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84\u201392.","journal-title":"J Clin Virol"},{"key":"1305_CR82","doi-asserted-by":"crossref","unstructured":"Lieberman PM. Virology. Epstein-Barr virus turns 50. Science. 2014;343(6177):1323\u20135.","DOI":"10.1126\/science.1252786"},{"key":"1305_CR83","doi-asserted-by":"publisher","first-page":"734293","DOI":"10.3389\/fimmu.2021.734293","volume":"12","author":"S Han","year":"2021","unstructured":"Han S, Tay JK, Loh CJL, Chu AJM, Yeong JPS, Lim CM, et al. Epstein-Barr virus epithelial cancers-A comprehensive understanding to drive novel therapies. Front Immunol. 2021;12:734293.","journal-title":"Front Immunol"},{"issue":"2","key":"1305_CR84","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/gutjnl-2013-304531","volume":"63","author":"MC Camargo","year":"2014","unstructured":"Camargo MC, Kim W-H, Chiaravalli AM, Kim K-M, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236\u201343.","journal-title":"Gut"},{"issue":"4","key":"1305_CR85","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10120-015-0565-1","volume":"19","author":"JH Park","year":"2016","unstructured":"Park JH, Kim EK, Kim YH, Kim J-H, Bae YS, Lee YC, et al. Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer. Gastric Cancer. 2016;19(4):1041\u201351.","journal-title":"Gastric Cancer"},{"issue":"4","key":"1305_CR86","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.3892\/ijo.2015.2856","volume":"46","author":"A Shinozaki-Ushiku","year":"2015","unstructured":"Shinozaki-Ushiku A, Kunita A, Fukayama M. Update on Epstein-Barr virus and gastric cancer (review). Int J Oncol. 2015;46(4):1421\u201334.","journal-title":"Int J Oncol"},{"issue":"2","key":"1305_CR87","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5009\/gnl.2011.5.2.143","volume":"5","author":"H-J Song","year":"2011","unstructured":"Song H-J, Kim K-M. Pathology of Epstein-Barr virus-associated gastric carcinoma and its relationship to prognosis. Gut Liver. 2011;5(2):143\u20138.","journal-title":"Gut Liver"},{"issue":"1","key":"1305_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5230\/jgc.2016.16.1.1","volume":"16","author":"J Cho","year":"2016","unstructured":"Cho J, Kang M-S, Kim K-M. Epstein-Barr virus-associated gastric carcinoma and specific features of the accompanying immune response. J Gastric Cancer. 2016;16(1):1\u20137.","journal-title":"J Gastric Cancer"},{"issue":"3","key":"1305_CR89","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1053\/j.gastro.2009.05.001","volume":"137","author":"G Murphy","year":"2009","unstructured":"Murphy G, Pfeiffer R, Camargo MC, Rabkin CS. Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location. Gastroenterology. 2009;137(3):824\u201333.","journal-title":"Gastroenterology"},{"issue":"6","key":"1305_CR90","doi-asserted-by":"publisher","first-page":"534","DOI":"10.2174\/1568009616666160926124923","volume":"17","author":"A Morales-Sanchez","year":"2017","unstructured":"Morales-Sanchez A, Fuentes-Panana EM. Epstein-Barr virus-associated gastric cancer and potential mechanisms of oncogenesis. Curr Cancer Drug Targets. 2017;17(6):534\u201354.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"1305_CR91","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","volume":"11","author":"H Nakano","year":"2021","unstructured":"Nakano H, Saito M, Nakajima S, Saito K, Nakayama Y, Kase K, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep. 2021;11(1):1982.","journal-title":"Sci Rep"},{"issue":"1","key":"1305_CR92","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1186\/s12885-023-11654-z","volume":"23","author":"FCA de Moraes","year":"2023","unstructured":"de Moraes FCA, Pasqualotto E, Lopes LM, Cavalcanti Souza ME, de Oliveira Rodrigues ALS, de Almeida AM, et al. PD-1\/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC Cancer. 2023;23(1):1166.","journal-title":"BMC Cancer"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01305-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01305-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T18:54:54Z","timestamp":1757444094000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01305-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1305"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01305-w","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"16 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. Furthermore, no patients were involved in the design, conduct, or interpretation of our study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interest"}}],"article-number":"178"}}